Valuation: H&R GmbH & Co KgaA

Market Cap 227M 262M 213M 194M 367M 24.92B 372M 2.49B 976M 12.45B 982M 961M 41.45B P/E 2026 *
4.72x
P/E 2027 * 16.5x
Enterprise Value 250M 288M 234M 214M 404M 27.43B 409M 2.74B 1.07B 13.71B 1.08B 1.06B 45.62B EV / Sales 2026 *
0.18x
EV / Sales 2027 * 0.17x
Free-Float
21.97%
Yield 2026 *
0.82%
Yield 2027 * 0.82%
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25-08-24 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
25-08-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
25-05-13 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-16 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
25-04-08 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-26 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
25-03-26 H&R GmbH & Co. KGaA Announces Postponement of the Publication of the Consolidated Financial Statements and the Annual Report 2024 CI
Manager TitleAgeSince
Chief Executive Officer 61 2015-12-31
Investor Relations Contact - 2005-12-31
Director TitleAgeSince
Chairman 62 2012-04-16
Director/Board Member 71 2011-04-30
Director/Board Member 69 2011-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 262M
+0.25%+1.75%+10.08%+31.67% 127B
+0.85%+23.10%+378.55%+155.00% 43.85B
-0.88%+1.92%-12.32%-40.53% 40.39B
+0.70%-2.08%+22.74%-22.34% 34.76B
+1.43%-1.72%+49.11%+68.97% 25.28B
+0.25%+8.76%+73.58%+254.10% 20.17B
+8.18%+19.45%+352.53%+671.89% 17.94B
+4.08%+1.65%+24.00%-35.81% 19.85B
+1.34%+3.13%+14.43%+13.90% 18.19B
Average +1.62%+6.14%+101.41%+121.87% 38.61B
Weighted average by Cap. +1.02%+4.27%+80.47%+77.33%

Financials

2026 *2027 *
Net sales 1.4B 1.61B 1.31B 1.2B 2.26B 153B 2.29B 15.29B 6B 76.54B 6.04B 5.91B 255B 1.36B 1.57B 1.28B 1.17B 2.2B 150B 2.23B 14.92B 5.86B 74.72B 5.89B 5.77B 249B
Net income 39.5M 45.52M 36.99M 33.83M 63.87M 4.34B 64.71M 433M 170M 2.17B 171M 167M 7.21B 16.5M 19.01M 15.45M 14.13M 26.68M 1.81B 27.03M 181M 70.94M 905M 71.39M 69.84M 3.01B
Net Debt 22.87M 26.35M 21.41M 19.59M 36.98M 2.51B 37.46M 251M 98.31M 1.25B 98.94M 96.79M 4.17B 8.65M 9.97M 8.1M 7.41M 13.99M 950M 14.17M 94.77M 37.19M 474M 37.43M 36.61M 1.58B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-